Drugs / BR1018C
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06165250 | Apr 2024 → Nov 2025 | essential hypertension, hyperlipoproteinemia | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BR1018C | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06165250 ↗ |